Through a high-throughput chemical screening of 2160 compounds, we identified Tyrosyl-DNA phosphodiesterase 1 (TDP1) as a novel modifier for DM2 therapeutic intervention. The gene discussed is TDP1; the disease is myotonic dystrophy type 2.